Liu Chenguang, Gao Jingjie, Cheng Yuying, Zhang Shanshan, Fu Caiyun
Zhejiang Provincial Engineering Research Center of New Technologies and Applications for Targeted Therapy of Major Diseases, College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou 310018, P. R. China.
Department of Orthopaedics Shanghai Key Laboratory for Prevention and Treatment of Bone and Joint Diseases, Shanghai Institute of Traumatology and Orthopaedics, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, P. R. China.
Regen Biomater. 2024 Nov 21;12:rbae135. doi: 10.1093/rb/rbae135. eCollection 2025.
Low tumor enrichment remains a serious and urgent problem for drug delivery in cancer therapy. Accurate targeting of tumor sites is still a critical aim in cancer therapy. Though there have been a variety of delivery strategies to improve the tumor targeting and enrichment, biological barriers still cause most delivered guests to fail or be excreted before they work. Recently, cell membrane-based systems have attracted a huge amount of attention due to their advantages such as easy access, good biocompatibility and immune escape, which contribute to their biomimetic structures and specific surface proteins. Furthermore, cancer cell membrane-based delivery systems are referred to as homologous-targeting function in which they exhibit significantly high adhesion and internalization to homologous-type tumor sites or cells even though the exact mechanism is not entirely revealed. Here, we summarize the sources and characterizations of cancer cell membrane systems, including reconstructed single or hybrid membrane-based nano-/microcarriers, as well as engineered cancer cells. Additionally, advanced applications of these cancer cell membrane systems in cancer therapy are categorized and summarized according to the components of membranes. The potential factors related to homologous targeting of cancer cell membrane-based systems are also discussed. By discussing the applications, challenges and opportunities, we expect the cancer cell membrane-based homologous-targeting systems to have a far-reaching development in preclinic or clinics.
在癌症治疗的药物递送中,低肿瘤富集仍然是一个严重且紧迫的问题。精确靶向肿瘤部位仍是癌症治疗的关键目标。尽管已经有多种递送策略来改善肿瘤靶向性和富集,但生物屏障仍导致大多数递送的客体在发挥作用之前失效或被排出。近来,基于细胞膜的系统因其诸如易于获取、良好的生物相容性和免疫逃逸等优势而备受关注,这些优势得益于它们的仿生结构和特定的表面蛋白。此外,基于癌细胞膜的递送系统具有同源靶向功能,即它们对同源类型的肿瘤部位或细胞表现出显著高的粘附和内化作用,尽管确切机制尚未完全揭示。在此,我们总结了癌细胞膜系统的来源和特性,包括基于重构的单膜或混合膜的纳米/微载体以及工程化癌细胞。此外,根据膜的成分对这些癌细胞膜系统在癌症治疗中的先进应用进行了分类和总结。还讨论了与基于癌细胞膜系统的同源靶向相关的潜在因素。通过讨论应用、挑战和机遇,我们期望基于癌细胞膜的同源靶向系统在临床前或临床中有深远的发展。